Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this
 study is to test whether insulin detemir is a safe and at least as effective alternative to
 insulin glargine for the control of blood glucose in basal/bolus therapy in patients with
 type I diabetes.
Inclusion Criteria:

 -  Type 1 diabetes for at least 12 months

 -  Current treatment with basal-bolus insulin regimen for more than or equal to 3 months

 -  HbA1c less than or equal to 11.0%

 Exclusion Criteria:

 -  Proliferative retinopathy or maculopathy

 -  Recurrent major hypoglycaemia

 -  Impaired hepatic or renal function

 -  Cardiac problems or uncontrolled hypertension